Sore Throat News and Research

RSS

FDA approves novel stomach-draining device to treat obesity

The U.S. Food and Drug Administration today approved a new obesity treatment device that uses a surgically-placed tube to drain a portion of the stomach contents after every meal.

15 Jun 2016

Study estimates 30% of outpatient oral antibiotic prescription in the U.S as inappropriate

An estimated 30 percent of outpatient oral antibiotic prescriptions in the U.S. in 2010-2011 may have been inappropriate, findings that support the need for establishing a goal for outpatient antibiotic stewardship, according to a study appearing in the May 3 issue of JAMA.

4 May 2016

New KidsMD Alexa skill device allows parents to get easier to access medical information

"My child has a fever of 101. Should I be concerned?" Through a new skill created for Amazon Alexa-enabled devices, parents will now be able to ask Alexa a variety of questions around fever and other common symptoms. The KidsMD Alexa skill was developed by the Innovation & Digital Health Accelerator team at Boston Children's Hospital and launched today.

13 Apr 2016

Inflectra (infliximab-dyyb) approved for multiple indications

The U.S. Food and Drug Administration today approved Inflectra (infliximab-dyyb) for multiple indications. Inflectra is administered by intravenous infusion. This is the second biosimilar approved by the FDA.

6 Apr 2016

Investigators predict that new pneumonia epidemic in Beijing will likely to continue for longer time

Mycoplasma pneumoniae infections began rising in Beijing last spring, and by December, this pathogen was found in more than half of hospitalized children suffering from pneumonia in that city, according to investigators from the Capital Institute of Pediatrics, Beijing, China.

2 Apr 2016

Omalizumab treatment significantly decreases colds in inner-city children with allergic asthma

Treatment with omalizumab significantly decreases the number of colds in inner-city children with allergic asthma, researchers reported at a press conference today at the American Academy of Allergy, Asthma and Immunology 2016 Annual Meeting in Los Angeles. Omalizumab, sold under the brand name Xolair, is an injectable antibody that can be used to treat asthma cases not controlled by inhaled corticosteroids.

7 Mar 2016

Cherry-flavoured e-cigarette users may be exposed to potentially harmful chemical

An analysis of 145 different electronic-cigarette flavoring products reveals that many e-cigarette users may be exposed to a potentially harmful chemical. In a research letter published online today in the peer-reviewed journal Thorax, a research team led by Maciej Goniewicz, PhD, PharmD, of Roswell Park Cancer Institute reports that high levels of the respiratory irritant benzaldehyde were detected in the vapor from most of the flavored nicotine products they studied, with the highest concentrations in vapor from cherry-flavored products.

1 Feb 2016

Turing Pharmaceuticals emphasizes continued availability of Daraprim

Turing Pharmaceuticals AG, a privately-held biopharmaceutical company focused on developing and commercializing innovative treatments for serious diseases and conditions, today emphasizes the continued availability of Daraprim and cautions healthcare providers of proposed alternatives to Daraprim.

20 Dec 2015

SLU infectious diseases experts answer flu season questions

A cure for the common cold isn't in the crystal ball of an infectious diseases researcher and physician at Saint Louis University's Center for Vaccine Development.

23 Nov 2015

Shared decision making between doctors and patients useful in fight against antibiotic resistance

A new Cochrane Review published today shows that when doctors and patients are encouraged to discuss the need for prescribing antibiotics for acute respiratory infections jointly, fewer are prescribed. This may be useful in the fight against antibiotic resistance.

12 Nov 2015

Researchers track re-emergence of scarlet fever-causing bacteria

An international study led by University of Queensland researchers has tracked the re-emergence of a childhood disease which had largely disappeared over the past 100 years.

4 Nov 2015

Johns Hopkins doctors urge people to get vaccinated against influenza virus

Flu season is upon us again — and yes, you should get the flu vaccine. Doctors at the Johns Hopkins University School of Medicine say everyone 6 months of age and older should get vaccinated against the influenza virus this year.

31 Oct 2015

Novartis announces FDA approval of dual combination bronchodilator Utibron Neohaler for COPD patients

Novartis announced today that the US Food and Drug Administration has approved the dual combination bronchodilator Utibron Neohaler (indacaterol/glycopyrrolate) inhalation powder for the long-term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. It is not indicated to treat asthma or sudden symptoms of COPD.

30 Oct 2015

Boehringer Ingelheim, Lilly announce availability of Synjardy tablets in U.S. pharmacies

Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company announced that Synjardy (empagliflozin/metformin hydrochloride) tablets are now available by prescription in pharmacies across the United States.

14 Oct 2015

FDA approves Promacta to treat pediatric patients with chronic immune thrombocytopenic purpura

The U.S. Food and Drug Administration today approved Promacta (eltrombopag) to treat low blood platelet count in pediatric patients – ages one year and older – with a rare blood disorder called chronic immune thrombocytopenic purpura (ITP). Promacta can be used in these children when they have not achieved an appropriate response using other ITP medicines or surgery to remove the spleen.

9 Oct 2015

Phase II psoriasis study shows efficacy of Boehringer Ingelheim's BI 655066 over ustekinumab

New results from a Phase II head-to-head psoriasis study showed superior efficacy of Boehringer Ingelheim's investigational biologic compound BI 655066, over ustekinumab. After nine months, 69 percent of patients with moderate-to-severe plaque psoriasis maintained clear or almost clear skin (PASI 90) with BI 655066 in the higher dose group compared to 30 percent of patients on ustekinumab.

8 Oct 2015

Sore Throat News and Research

FDA approves novel stomach-draining device to treat obesity

Study estimates 30% of outpatient oral antibiotic prescription in the U.S as inappropriate

New KidsMD Alexa skill device allows parents to get easier to access medical information

Inflectra (infliximab-dyyb) approved for multiple indications

Investigators predict that new pneumonia epidemic in Beijing will likely to continue for longer time

Omalizumab treatment significantly decreases colds in inner-city children with allergic asthma

Cherry-flavoured e-cigarette users may be exposed to potentially harmful chemical

Turing Pharmaceuticals emphasizes continued availability of Daraprim

SLU infectious diseases experts answer flu season questions

Shared decision making between doctors and patients useful in fight against antibiotic resistance

Researchers track re-emergence of scarlet fever-causing bacteria

Johns Hopkins doctors urge people to get vaccinated against influenza virus

Novartis announces FDA approval of dual combination bronchodilator Utibron Neohaler for COPD patients

Boehringer Ingelheim, Lilly announce availability of Synjardy tablets in U.S. pharmacies

FDA approves Promacta to treat pediatric patients with chronic immune thrombocytopenic purpura

Phase II psoriasis study shows efficacy of Boehringer Ingelheim's BI 655066 over ustekinumab

Air pollution from forest fires aggravates children’s respiratory health

Study: Influenza vaccines offer sustained protection up to 6 months during flu season

STIOLTO RESPIMAT Inhalation Spray now available for treatment of COPD across the U.S.

New telemedicine plan for underinsured, uninsured individuals

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News